Evidence map›Paper›PMID 32583431›Full record

Trial reportBritish journal of haematology2021

Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105).

Dai Maruyama, Shinsuke Iida, Gakuto Ogawa, Noriko Fukuhara, Sachiko Seo, Kana Miyazaki, Makoto Yoshimitsu, Junya Kuroda, Norifumi Tsukamoto, Hideki Tsujimura and 15 more

Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 1 country.

Dai MaruyamaDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.ORCID 0000-0003-0654-6920
Shinsuke IidaDepartment of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan.
Gakuto OgawaJCOG Data Center/Operating Office, National Cancer Center Hospital, Tokyo, Japan.
Noriko FukuharaDepartment of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.
Sachiko SeoDepartment of Hematology, National Cancer Center Hospital East, Kashiwa, Japan.
Kana MiyazakiDepartment of Hematology and Oncology, Mie University School of Medicine, Tsu, Japan.
Makoto YoshimitsuDepartment of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.ORCID 0000-0002-5935-0385
Junya KurodaDivision of Hematology and Oncology, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID 0000-0001-6130-1550
Norifumi TsukamotoDepartment of Hematology, Gunma University, Maebashi, Japan.
Hideki TsujimuraDivision of Hematology-Oncology, Chiba Cancer Center, Chiba, Japan.
Akira HangaishiDivision of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
Takahiro YamauchiDepartment of Hematology and Oncology, University of Fukui Hospital, Fukui, Japan.
Takahiko UtsumiDepartment of Hematology, Shiga General Hospital, Moriyama, Japan.
Ishikazu MizunoDivision of Hematology, Hyogo Cancer Center, Akashi, Japan.
Yasushi TakamatsuDivision of Medical Oncology, Hematology and Infectious Diseases, Fukuoka University Hospital, Fukuoka, Japan.
Yasuyuki NagataDepartment of Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Koichiro MinauchiDepartment of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
Eiichi OhtsukaDepartment of Hematology, Oita Prefectural Hospital, Oita, Japan.
Ichiro HanamuraDivision of Hematology, Aichi Medical University, Nagakute, Japan.
Shinichiro YoshidaDepartment of Hematology, National Hospital Organization Nagasaki Medical Center, Ohmura, Japan.
Satoshi YamasakiDepartment of Hematology and Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Japan.
Youko SuehiroDepartment of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Yutaro KamiyamaDepartment of Clinical Oncology and Hematology, The Jikei University Hospital, Tokyo, Japan.
Kunihiro TsukasakiDepartment of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Hirokazu NagaiDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Aichi Medical University · JPChiba Cancer Center · JPFukuoka University Hospital · JPGunma University · JPHamamatsu University · JPHyogo Prefectural Cancer Center · JPJapan Clinical Cancer Research Organization · JPKagoshima University Hospital · JPKyoto Prefectural University of Medicine · JPMie University · JPNagasaki Medical Center · JPNagoya City University Hospital · JPNational Cancer Center Hospital East · JPNational Hospital Organization · JPNational Hospital Organization Kyushu Cancer Center · JPNational Kyushu Medical Center · JPNTT Medical Center · JPOita Prefectural Hospital · JPSaitama International Medical Center · JPSapporo Hokuyu Hospital · JP

Funding

AMED JP16ck0106077AMED JP19ck0106348Ministry of Health, Labour and Welfare of Japan H26-kakushin-teki-gan-ippan-074National Cancer Center Research and Development Funds 26-A-4National Cancer Center Research and Development Funds 29-A-3
6 · The paper itself

Abstract

We conducted a randomised phase II study to determine the optimal dose and schedule of melphalan, prednisone, and bortezomib (MPB) (jRCTs031180097). Transplant-ineligible untreated multiple myeloma patients were randomised to Arm A (twice weekly bortezomib in one six-week cycle followed by eight five-week cycles of four times once weekly bortezomib with melphalan and prednisolone on days 1-4) or Arm B (nine four-week cycles of three times once weekly bortezomib with melphalan and prednisolone on days 1-4). The primary end-point was complete response (CR) rate. Of 91 patients randomised to two arms, 88 were eligible. The median cumulative bortezomib doses were 45·8 and 35·1 mg/m

Indexed as

AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBortezomibFemaleHumansMaleMelphalanMultiple MyelomaPrednisoloneSurvival AnalysisTreatment OutcomeBortezomibMelphalanPrednisoloneclinical studieselderymultiple myeloma

Identifiers

PMID32583431
PMCPMC7891591
OpenAlexW3037977086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.